202 related articles for article (PubMed ID: 22123719)
1. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.
Doçi CL; Mankame TP; Langerman A; Ostler KR; Kanteti R; Best T; Onel K; Godley LA; Salgia R; Lingen MW
Int J Gynecol Pathol; 2012 Jan; 31(1):15-24. PubMed ID: 22123719
[TBL] [Abstract][Full Text] [Related]
2. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
3. The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7.
Mankame TP; Lingen MW
Neoplasia; 2012 Dec; 14(12):1213-22. PubMed ID: 23308053
[TBL] [Abstract][Full Text] [Related]
4. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix.
Cohen Y; Singer G; Lavie O; Dong SM; Beller U; Sidransky D
Clin Cancer Res; 2003 Aug; 9(8):2981-4. PubMed ID: 12912945
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo.
Li X; Wu X; Li Y; Cui Y; Tian R; Singh N; Ding M; Yang Y; Gao Y
Oncol Rep; 2019 Apr; 41(4):2351-2360. PubMed ID: 30720133
[TBL] [Abstract][Full Text] [Related]
6. Identification and functional analysis of NOL7 nuclear and nucleolar localization signals.
Zhou G; Doçi CL; Lingen MW
BMC Cell Biol; 2010 Sep; 11():74. PubMed ID: 20875127
[TBL] [Abstract][Full Text] [Related]
7. NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype.
Hasina R; Pontier AL; Fekete MJ; Martin LE; Qi XM; Brigaudeau C; Pramanik R; Cline EI; Coignet LJ; Lingen MW
Oncogene; 2006 Jan; 25(4):588-98. PubMed ID: 16205646
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of the human NOL7 gene promoter.
Mankame TP; Zhou G; Lingen MW
Gene; 2010 May; 456(1-2):36-44. PubMed ID: 20206243
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Zhang Z; Huettner PC; Nguyen L; Bidder M; Funk MC; Li J; Rader JS
Oncogene; 2006 Aug; 25(39):5436-45. PubMed ID: 16607278
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.
Yang WT; Zheng PS
PLoS One; 2014; 9(2):e88827. PubMed ID: 24551169
[TBL] [Abstract][Full Text] [Related]
11. Loss of LDOC1 expression by promoter methylation in cervical cancer cells.
Buchholtz ML; Jückstock J; Weber E; Mylonas I; Dian D; Brüning A
Cancer Invest; 2013 Nov; 31(9):571-7. PubMed ID: 24125169
[TBL] [Abstract][Full Text] [Related]
12. Aberrant promoter methylation and silencing of RASSF2A gene in cervical cancer.
Zhang X; Ma Y; Wu Y; Lin L; Ma X; Zhang Y
J Obstet Gynaecol Res; 2014 May; 40(5):1375-81. PubMed ID: 24605823
[TBL] [Abstract][Full Text] [Related]
13. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.
Seng TJ; Low JS; Li H; Cui Y; Goh HK; Wong ML; Srivastava G; Sidransky D; Califano J; Steenbergen RD; Rha SY; Tan J; Hsieh WS; Ambinder RF; Lin X; Chan AT; Tao Q
Oncogene; 2007 Feb; 26(6):934-44. PubMed ID: 16862168
[TBL] [Abstract][Full Text] [Related]
14. Mutational, epigenetic and expressional analyses of caveolin-1 gene in cervical cancers.
Chan TF; Su TH; Yeh KT; Chang JY; Lin TH; Chen JC; Yuang SS; Chang JG
Int J Oncol; 2003 Sep; 23(3):599-604. PubMed ID: 12888893
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of Rab39a promotes epithelial to mesenchymal transition of cervical cancer through AKT signaling.
Zou C; Fan J; He M; Xu Y; Wang K; Cai Y; Li M
Exp Cell Res; 2019 May; 378(2):139-148. PubMed ID: 30826396
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
17. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.
Yin FF; Wang N; Bi XN; Yu X; Xu XH; Wang YL; Zhao CQ; Luo B; Wang YK
Virol J; 2016 Apr; 13():60. PubMed ID: 27044426
[TBL] [Abstract][Full Text] [Related]
18. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer.
Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G
BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473
[TBL] [Abstract][Full Text] [Related]
19. Lack of TNFalpha mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation.
Kloth JN; Gorter A; ter Haar N; Corver WE; Jordanova ES; Kenter GG; Fleuren GJ
Mol Immunol; 2008 Jan; 45(1):152-9. PubMed ID: 17560652
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of the DLC‑1 gene and its inhibitory effect on human colon cancer.
Dai Z; Jin Y
Oncol Rep; 2013 Sep; 30(3):1511-7. PubMed ID: 23783552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
